OncLive TV

Jim M. Koeller, MS FHOPA, discusses the heterogeneity of biologics.

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Bradley G. Somer, MD, discusses lowering the cost of cancer care with biosimilars.

Kathleen G. Essel, MD, discusses the rationale to explore quantitative computed tomography image feature analysis in gynecologic cancers.

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Charles A. Leath III MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses results of the phase III GOG 240 trial in advanced cervical cancer.

Lee S. Schwartzberg, MD, FACP, chief medical officer, OneOncology, chief and professor of medicine, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, and executive director, West Cancer Center, discusses the use of therapeutic biosimilars in breast cancer.

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.